Stock XOMAO XOMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

XOMA Corporation Share Price Nasdaq

Equities

XOMAO

US98419J4040

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:00:01 02/05/2024 am IST 		5-day change 1st Jan Change
25.1 USD +0.84% Intraday chart for XOMA Corporation +0.40% -0.08%
30/04 XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million. CI
29/04 Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target MT

Financials

Sales 2024 * 14M 1.17B Sales 2025 * 23.57M 1.96B Capitalization 296M 24.67B
Net income 2024 * -27M -2.25B Net income 2025 * -19M -1.58B EV / Sales 2024 * 21.1 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 12.6 x
P/E ratio 2024 *
-10.7 x
P/E ratio 2025 *
-15.1 x
Employees 13
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.58%
More Fundamentals * Assessed data

Chart XOMA Corporation

Dynamic Chart

Latest news about XOMA Corporation

XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million. CI
Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target MT
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc.. CI
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sector Update: Health Care Stocks Advance Friday Afternoon MT
XOMA Agrees to Acquire Kinnate Biopharma MT
XOMA Corporation entered into a definitive merger agreement to acquire Kinnate Biopharma Inc. for approximately $120 million. CI
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million MT
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million. CI
XOMA Names Owen Hughes CEO, Jack Wyszomierski Chairman; to Make $1 Million Milestone Payment MT
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol DJ
Xoma Names Owen Hughes as Chief Executive Officer CI
Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors CI
XOMA Authorizes $50 Million Share Buyback Program MT
XOMA Authorizes $50 Million Share Buyback Program MT
More news

Analyst Recommendations on XOMA Corporation

Leerink Partners Starts XOMA With Outperform Rating, $40 Price Target MT
HC Wainwright Adjusts Price Target on XOMA to $74 From $69, Maintains Buy Rating MT
XOMA : Wedbush Suspended Coverage on XOMA MT
XOMA : HC Wainwright Adjusts XOMA's Price Target to $69 from $56, Keeps Buy Rating MT
XOMA : Aegis Capital Adjusts XOMA Price Target to $56 From $60, Maintains Buy Rating MT
More recommendations

Press releases XOMA Corporation

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% AQ
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) AQ
XOMA : Acquisition/Asset Disposal - Form 8-K PU
XOMA Corporation Announces Closing of Tender Offer AQ
XOMA Declares Quarterly Preferred Stock Dividends AQ
More press releases

News in other languages on XOMA Corporation

Obseva: Organon rétrocède la licence pour Ebopiprant, paiement d'étape éteint
Obseva: Organon gibt Lizenz für Ebopiprant zurück - Meilensteinanspruch erlischt
Kuros: le déploiement commercial du Magnetos a creusé le déficit en 2022
Obseva réduit la voilure autour de ses actifs restants
Obseva: la demande de retrait de sursis concordataire est acceptée
More news

Quotes and Performance

1 day+0.84%
1 week+0.40%
Current month+0.84%
1 month+0.24%
3 months+1.99%
6 months+14.72%
Current year-0.08%
More quotes

Highs and lows

1 week
24.82
Extreme 24.82
25.10
1 month
24.82
Extreme 24.82
25.25
Current year
23.50
Extreme 23.5001
25.85
1 year
20.43
Extreme 20.43
25.85
3 years
20.43
Extreme 20.43
27.95
5 years
20.43
Extreme 20.43
27.95
10 years
20.43
Extreme 20.43
27.95
More quotes

Managers and Directors - XOMA Corporation

Managers TitleAgeSince
Owen Hughes CEO
 Chief Executive Officer 49 01/23/01
Thomas Burns DFI
 Director of Finance/CFO 50 14/06/14
Bradley Sitko CIO
 Chief Investment Officer 43 03/23/03
Members of the board TitleAgeSince
Heather Franklin BRD
 Director/Board Member 58 06/21/06
Jack Wyszomierski CHM
 Chairman 68 26/10/26
Joseph Limber BRD
 Director/Board Member 71 12/12/12
More insiders

Quotes

Date Price Change Volume
01/24/01 25.1 +0.84% 1,089
29/24/29 24.89 -0.32% 5,048
26/24/26 24.97 -0.12% 1,560
25/24/25 25 -0.00% 977
24/24/24 25 0.00% 650

Delayed Quote Nasdaq, May 02, 2024 at 02:00 am IST

More quotes

Company Profile

XOMA Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Sector
Biotechnology & Medical Research
Calendar
07/05/2024 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Ratings for XOMA Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.44 USD
Average target price
57 USD
Spread / Average Target
+124.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.65% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.75% 101B
ARGENX SE Stock argenx SE
+6.32% 23.07B
BIONTECH SE Stock BioNTech SE
-12.60% 22.23B
GENMAB A/S Stock Genmab A/S
-6.26% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.17% 16.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.12% 14.07B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.47% 12.35B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. XOMAO Stock